Šajā tīmekļa vietnē tiek izmantotas sīkdatnes. Turpinot lietot šo vietni, jūs piekrītat sīkdatņu izmantošanai. Uzzināt vairāk.
Teksta versija
LEGAL ACTS OF THE REPUBLIC OF LATVIA
home
 
The translation of this document is outdated.
Translation validity: 16.10.2017.–09.01.2019.
Amendments not included: 08.01.2019., 15.10.2019.
Text consolidated by Valsts valodas centrs (State Language Centre) with amending regulations of:

12 May 2009 [shall come into force from 16 May 2009];
3 November 2009 [shall come into force from 28 November 2009];
17 May 2011 [shall come into force from 21 May 2011];
12 June 2012 [shall come into force from 16 August 2012];
11 December 2012 [shall come into force from 23 February 2013];
21 May 2013 [shall come into force from 24 May 2013];
19 August 2014 [shall come into force from 23 August 2014];
26 May 2015 [shall come into force from 1 June 2015];
26 April 2016 [shall come into force from 1 May 2016];
7 March 2017 [shall come into force from 17 March 2017];
10 October 2017 [shall come into force from 16 October 2017].

If a whole or part of a paragraph has been amended, the date of the amending regulation appears in square brackets at the end of the paragraph. If a whole paragraph or sub-paragraph has been deleted, the date of the deletion appears in square brackets beside the deleted paragraph or sub-paragraph.


Republic of Latvia

Cabinet
Regulation No. 847

Adopted 8 November 2005

Regulations Regarding Narcotic Substances, Psychotropic Substances and Precursors to be Controlled in Latvia

Issued pursuant to
Section 3, Paragraph two of the law On Procedures for the Legal Trade
of Narcotic and Psychotropic Substances and Medicinal Products

1. This Regulation prescribes narcotic substances, psychotropic substances and precursors to be controlled in Latvia.

2. The following shall be controlled in Latvia in accordance with the laws and regulations governing the circulation of narcotic and psychotropic medicinal products and substances:

2.1. prohibited especially dangerous narcotic substances and equivalent psychotropic substances and plants (Schedule I of Narcotic Substances, Psychotropic Substances and Precursors to be Controlled in Latvia) (Annex 1);

2.2. very dangerous narcotic substances and equivalent psychotropic substances permitted for medical and scientific use (Schedule II of Narcotic Substances, Psychotropic Substances and Precursors to be Controlled in Latvia) (Annex 2);

2.3. dangerous psychotropic substances that can be abused (Schedule III of Narcotic Substances, Psychotropic Substances and Precursors to be Controlled in Latvia) (Annex 3);

2.4. derivatives, isomers, structural analogues, active metabolites, esters, ethers, and salts (also salts of isomers, structural analogues, active metabolites, esters, and ethers) of the narcotic substances and psychotropic substances included in Schedule I, II or III of Narcotic Substances, Psychotropic Substances and Precursors to be Controlled in Latvia, as well as medicinal products that contain the narcotic and psychotropic substances included in the abovementioned Schedules, unless exceptions are specified in laws and regulations;

2.5. the precursors referred to in Council Regulation (EC) No 111/2005 of 22 December 2004 laying down rules for the monitoring of trade between the Community and third countries in drug precursors and in Annexes to Regulation (EC) No 273/2004 of the European Parliament and of the Council of 11 February 2004 on drug precursors;

2.6. parts of plants, dried plants, pressed plants, powders, tablets, capsules, extracts, tinctures and any other products of the abovementioned plants that contain the substances included in the Schedule I of Narcotic Substances, Psychotropic Substances and Precursors to be Controlled in Latvia, except products that are allowed for distribution in accordance with the laws and regulations regarding food handling.

[12 May 2009; 3 November 2009; 26 May 2015; 7 March 2017]

2.1 The State Agency of Medicines shall notify regarding changes in Schedules I, II and III of Narcotic Substances, Psychotropic Substances and Precursors to be Controlled in Latvia by publishing the information on the website of the State Agency of Medicines (http://www.zva.gov.lv).

[17 May 2011]

3. Cabinet Regulation No. 35 of 20 January 2004, Regulations regarding Schedules of Narcotic Substances, Psychotropic Substances and Precursors to be Controlled in Latvia (Latvijas Vēstnesis, 2004, No. 12), is repealed.

4. Sub-paragraph 7.18 of Annex 1 to this Regulation shall come into force on 1 January 2012.

[17 May 2011]

5. Paragraph 5 of Annex 2 to this Regulation shall come into force on 1 June 2011.

[17 May 2011]

Acting for the Prime Minister, Minister for Justice S. Āboltiņa

Minister for Health G. Bērziņš

 

Annex 1
Cabinet Regulation No. 847
8 November 2005

[11 December 2012; 21 May 2013; 19 August 2014; 26 May 2015; 26 April 2016; 7 March 2017; 10 October 2017]

Narcotic Substances, Psychotropic Substances and Precursors to be Controlled in Latvia

Schedule I

(Prohibited especially dangerous narcotic substances, equivalent psychotropic substances and plants, illegal handling and abuse of which endangers health)

1. Substances and plants classified in conformity with the Single Convention on Narcotic Drugs of 30 March 1961:

1.1. synthetic opioid analgesics:

No.

International non-proprietary name (INN)/trivial name

Number in the Chemical Abstracts Service
(hereinafter - CAS No.)

Chemical name

1.1.1.

alphacetylmethadol (INN)

1553-31-7

[(3R*,6R*)-6-dimethylamino-4,4-di(phenyl)heptan-3-yl] acetate

1.1.2.

MPPP, desmethylprodine

13147-09-6

(4-phenyl-1-methylpiperidin-4-yl)propanoate

1.1.3.

PEPAP

64-52-8

4-phenyl-1-(2-phenylethyl)piperidin-4-yl acetate

1.1.4.

AH-7921

55154-30-8

3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide

1.1.5.

U-47700

82657-23-6

3,4-dichloro-N-[(1R,2R)-2-(dimethylamino)cyclohexyl]-N-methylbenzamide

1.1.6.

U-51754

121279-74-1

2-(3,4-dichlorophenyl)-N-[2-(dimethylamino)cyclohexyl]-N-methylacetamide

1.2. morphinan derivatives:

No.

International non-proprietary name (INN)/trivial name

CAS No.

Chemical name

1.2.1.

heroin, morphine diacetate (INN)

561-27-3

(5α,6α)-7,8-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol diacetate

2.2.1.

desomorphine, Krokodil

427-00-9

4,5-α-epoxy-17-methylmorphinan-3-ol

1.3.2.

etorphine, Immobilon, M99

14521-96-1

(5alpha,7alpha)-7-(2-hydroxypentan-2-yl)-6-methoxy-17-methyl-4,5-epoxy-6,14-ethenomorphinan-3-ol

1.2.4.

acetorphine

25333-77-1

4,5α-epoxy-7α-(1-hydroxy-1-methylbutyl)-6-methoxy-17-methyl-6,14-endoetheno-morphinan-3-yl acetate

1.3. [10 October 2017]

1.4. products of plant origin with narcotic effect:

No.

Name

1.4.1. raw opium
1.4.2. poppy straw
1.4.3. preparations which are manufactured from any type of poppy if they contain narcotically active opium alkaloids: morphine, codeine, thebaine (extracts, infusions and brews with active substance content in any amount)
1.4.4. cannabis, cannabis resin, oil, extracts and tinctures
1.4.5. coca leaf

2. Substances and plants classified in conformity with the Convention on Psychotropic Substances of 21 February 1971:

2.1. phenethylamine derivatives:

No.

International non-proprietary name (INN)/trivial name

CAS No.

Chemical name

2.1.1.

mescaline

54-04-6

2-(3,4,5-trimethoxyphenyl)ethanamine

2.1.2.

fenethylline

3736-08-1

(RS)-1,3-dimethyl-7-[2-(1-phenylpropan-2-ylamino)ethyl]purine-2,6-dione

2.1.3.

fenproporex

16397-28-7

3-(1-phenylpropan-2-ylamino)propanenitrile

2.1.4.

phentermine

122-09-8

2-methyl-1-phenylpropan-2-amine

2.1.5.

mefenorex, Rondimen, Pondinil, Anexate

17243-57-1

3-chloro-N-(1-phenylpropan-2-yl)propan-1-amine

2.1.6.

4-methylaminorex

(±)-cis isomers-29493-77-4

4-methyl-5-phenyl-4,5-dihydro-1,3-oxazol-2-amine

2.1.7.

4,4′-DMAR

1445569-01-6

4-methyl-5-(4-methylphenyl)-4,5-dihydrooxazol-2-amine

2.2. natural substances and derivatives thereof:

No.

International non-proprietary name (INN)/trivial name

CAS No.

Chemical name

2.2.1.

[7 March 2017]

2.2.2.

7-hydroxymitragynine

174418-82-7

(αE,2S,3S,7aS,12bS)-3-Ethyl-1,2,3,4,6,7,7a,12b-octahydro-7a-hydroxy-8-methoxy-α-(methoxymethylene)indolo[2,3-a]quinolizine-2-acetic acid methyl ester

2.2.3.

mitragynine

6202-22-8

(E)-2-[(2S,3S)-3-ethyl-8-methoxy-1,2,3,4,6,7,12,12b-octahydroindolo[3,2-h]quinolizin-2-yl]-3-methoxyprop-2-enoic acid methyl ester

2.2.4.

salvinorin A

83729-01-5

(2S,4aR,6aR,7R,9S,10aS,10bR)-9-(acetyloxy)-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxododecahydro-2H-benzo[f]isochromene-7-carboxylate

2.2.5.

psilocin, psilotsin

520-53-6

3-[2-(dimethylamino)ethyl]-1H-indol-4-ol

2.2.6.

psilocybin

520-52-5

[3-(2-Dimethylaminoethyl)-1H-indol-4-yl] dihydrogen phosphate

2.3. compounds of other substances:

No.

International non-proprietary name (INN)/trivial name

CAS No.

Chemical name

2.3.1.

tenocyclidine TCP

21500-98-1

1-(1-(2-thienyl)cyclohexyl)piperidine

2.3.2.

eticyclidine PCE

2201-15-2

N-ethyl-1-phenylcyclohexanamine

2.3.3.

rolicyclidine, PHP, PCPY

2201-39-0

1-(1-phenylcyclohexyl)pyrrolidine

2.3.4.

amineptine

57574-09-1

7-[(10,11-dihydro-5H-dibenzo[a,d]-cyclohepten-5-yl)amino]heptanoic acid

2.3.5.

cathine

492-39-7

(1S,2S)-2-amino-1-phenylpropan-1-ol

2.3.6.

CRA-13

432047-72-8

1-naphthyl[4-(pentyloxy)-1-naphthyl]methanone

2.3.7.

dichloropane

146725-34-0

methyl-3-(3,4-dichlorophenyl)-8-azabicyclo[3.2.1]octane-4-carboxylate

2.4. plant products with psychotropic effect:

No.

Name

2.4.1.

catha edulis

2.4.2.

leonotis leonurus

2.4.3.

mitragyna speciosa (kratom)

2.4.4.

nymphaea caerulea

2.4.5.

salvia divinorum

2.4.6.

ephedra plant

2.4.7.

hallucinogenic mushrooms

2.5. psychotropic substances corresponding to the description*:

No.

Name

2.5.1.

2,5-dimethoxyphenyl-ethanamines

2,5-dimethoxyphenyl-ethanamine and any compound derived from 2- (2,5-dimethoxyphenyl)ethanamine:

a) by replacing hydrogen atom(s) on the benzene ring with one or several identical or different substitutes or substitutes which form a cyclic structure supplementing the benzene ring;

b) by replacing hydrogen atom(s) in an ethylene group with one or several alkyl groups;

c) by replacing one or two hydrogen atoms at the nitrogen atom with a not-replaced or replaced alkyl group or by including nitrogen atom in the atom cycle;

d) in any of the abovementioned compounds by replacing a hydrogen atom at the nitrogen atom, if it is free, with a not-replaced or replaced hydroxyl group or an acyl group

2.5.2.

3,4-methylenedioxyphenylethanamines

3,4-methylenedioxyphenylethanamine and any compound derived from 2-(3,4-methylenedioxyphenyl)ethanamine:

a) by replacing hydrogen atom(s) on the benzene ring with one or several identical or different substitutes or substitutes which form a cyclic structure supplementing the benzene ring;

b) by replacing hydrogen atom(s) in an ethylene group with one or several alkyl groups;

c) by replacing one or two hydrogen atoms at the nitrogen atom with a not-replaced or replaced alkyl group or by including nitrogen atom in the atom cycle;

d) in any of the abovementioned compounds by replacing a hydrogen atom at the nitrogen atom, if it is free, with a not-replaced or replaced hydroxyl group or an acyl group

2.5.3.

Amphetamines

1-phenylpropan-2-amine, its enantiomers and any compound derived from them:

a) by not replacing or by replacing one or two hydrogen atoms at the nitrogen atom with not-replaced or replaced alkyl group or including a nitrogen atom in the atom cycle;

b) by changing the benzene ring in the compounds referred to in Sub-paragraph "a" with another cyclic structure, different from the benzene ring, which may be replaced;

c) by replacing hydrogen atoms on the benzene ring of the compounds referred to in Sub-paragraph "a" with one or several identical or different substitutes or substitutes which form a cyclic structure supplementing the benzene ring;

d) by replacing one or several propyl group hydrogen atoms in any of the abovementioned compounds with not-replaced or replaced alkyl group or substitutes which form a benzene ring or a cyclic structure supplementing the cyclic structure referred to in Sub-Paragraph "b";

e) in any of the abovementioned compounds by replacing a hydrogen atom at the nitrogen atom, if it is free, with a not-replaced or replaced hydroxyl group or an acyl group

2.5.4.

2-aminoindanes

2-aminoindane or any compound derived from 2-aminoindane:

a) by replacing hydrogen atoms on the benzene ring with one or several identical or different substitutes or substitutes which form a cyclic structure supplementing the benzene ring;

b) by replacing one or two amino group hydrogen atoms with a not-replaced or replaced alkyl group or by including a nitrogen atom in the atom cycle

2.5.5.

Cyclic derivatives of 2-(2,5-dioxyphenyl)ethanamine

Any compound derived from 2-(2,5-dioxyphenyl)ethanamine:

a) in the condition 4 of hydrogen atoms by replacing with alkyl group, haloalkane group or halogen atom;

b) in addition by replacing hydrogen atom of one hydroxyl group with alkylen group or alkenylen group formed by cycle of 5 or 6 members with the benzene ring in ortho-condition;

c) in addition by replacing hydrogen atom of a second hydroxyl group with alkylen group or alkenylen group formed by cycle of 5 or 6 members with the benzene ring in ortho-condition, or methyl group;

d) in addition by not replacing or replacing one or two amino group hydrogen atoms or by including in the nitrogen atom cycle;

e) in addition by not replacing or replacing one or several ethylene group hydrogen atoms with a not-replaced or replaced alkyl group

2.5.6.

Cathinones

2-amino-1-phenylpropan-1-one and any compound derived from 2-amino-1-phenylpropan-1-one:

a) by not replacing or by replacing one or two hydrogen atoms at the nitrogen atom with not-replaced or replaced alkyl or alkoxy group or by including a nitrogen atom in the atom cycle;

b) by not replacing or by replacing one or two hydrogen atoms in propanone condition 3 with a not-replaced or replaced alkyl group or alkoxy group or amino group;

c) by changing the benzene ring in the compounds referred to in Sub-paragraph "a" or "b" with another cyclic structure, different from the benzene ring, which may be replaced;

d) by replacing hydrogen atoms on the benzene ring in any of the compounds referred to in Sub-paragraph "a" or "b" with one or several identical or different substitutes or substitutes which form a cyclic structure supplementing the benzene ring;

e) derivatives of any of the abovementioned compound carbonyl group or amino group, or both

2.5.7.

Piperazines

Any compound derived from piperazine:

a) by replacing a hydrogen atom at one nitrogen atom with a not-replaced or replaced phenyl group, not-replaced or replaced benzyl group or cyclohexyl group;

b) by not replacing or by replacing the hydrogen atom at a second nitrogen atom with a not-replaced or replaced methyl group

2.5.8.

Tryptamines and beta-(benzofuran-3-yl)ethanamines

Any derivative of beta-(indol-3-yl)ethanamine or beta-(benzofuran-3-yl)ethanamine**** which contains at least one substitute from rows "a", "b" and "c":

a) where hydrogen atom(s) on the benzene ring has (have) been replaced with one or several identical or different substitutes or substitutes which form a cyclic structure supplementing the benzene ring;

b) where hydrogen atoms in the ethylene group have been replaced with a not-replaced or replaced alkyl group;

c) where one or two hydrogen atoms in the amino group have been replaced with a not-replaced or replaced alkyl group, or a nitrogen atom has been included in the cycle

2.5.9.

1-Arylcyclohexylamines and (1-arylcyclohexyl)methanamines

1-arylcyclohexylamines (except ketamine) and (1-arylcyclohexyl)methanamines where the aryl group is a not-replaced or replaced benzene or thiophene cycle, one or two hydrogen atoms in the amino group have been replaced with a not-replaced or replaced alkyl group, or a nitrogen atom has been included in the cycle, and the cyclohexane cycle is not replaced or replaced with a carbonyl group, hydroxy group, alkoxy group or alkyl group

2.5.10.

Dibenzopyrans

Compounds derived from cannabinol*** modified on the ring A, replaced on the ring B, their homologues with different number of carbon atoms in the substitute in condition 3, cis-, trans- and optical isomers thereof, as well as their derivatives of hydroxyl group and halogen derivatives

2.5.11.

Cyclohexylphenols

Any compound derived from 2-(3-hydroxycyclohexyl)phenol:

a) by replacing hydrogen atom in condition 5 of phenol cycle;

b) in addition by not replacing or by replacing one or several hydrogen atoms in the cyclohexyl group

2.5.12.

Naphthylideneindenes and naphthylmethylindenes

Any compound derived from 1-naphthylideneindene or 1-naphthylmethylindene:

a) by not replacing or by replacing a hydrogen atom at indene C3 atom;

b) in addition by not replacing or by replacing in the compounds referred to in Sub-paragraph "a" one or several hydrogen atoms in the naphthyl group;

c) in addition by not replacing or by replacing in the compounds referred to in Sub-paragraph "a" or "b", or both, one or several hydrogen atoms in the indene cycle

2.5.13.

Naphthylmethylindoles

Any compound derived from (indol-3-yl)(naphth-1-yl)methane:

a) by not replacing or by replacing a hydrogen atom at the indole nitrogen atom;

b) in addition by not replacing or by replacing in the compounds referred to in Sub-paragraph "a" one or several hydrogen atoms in the naphthyl group;

c) in addition by not replacing or by replacing in the compounds referred to in Sub-paragraph "a" or "b", or both, one or several hydrogen atoms in the indole cycle

2.5.14.

Napthoylpyrroles

Any compound derived from 3-(1-naphthoyl)pyrrole:

a) by not replacing or by replacing a hydrogen atom at the pyrrole nitrogen atom;

b) in addition by not replacing or by replacing in the compounds referred to in Sub-paragraph "a" one or several hydrogen atoms in pyrrole cycle;

c) in addition by not replacing or by replacing in the compounds referred to in Sub-paragraph "a" or "b", or both, one or several hydrogen atoms in the naphthoyl group

2.5.15.

Derivatives of indole, azaindole and indazole-3-carbonyl

Derivatives of indole-3-carbonyl, derivatives of azaindol-3-carbonyl, and derivatives of indazole-3-carbonyl which are replaced at indole, azaindol or indazole cycle in condition 1 of the nitrogen atom with a not-replaced or replaced alkyl group and in condition 3 replaced at carbonyl group with:

• a not-replaced or replaced alkyl group or a cycloalkyl group;

• a not-replaced or replaced aromatic or heteroaromatic cycle;

• a not-replaced or replaced alcoxy group, aryloxy group, heteryloxy group;

• a replaced amino group

and in the indole or azaindol cycle condition 2 not-replaced or replaced with an alkyl group, and any of the abovementioned compounds which has additionally been replaced in an indole, azaindol or indazole cycle, including such where the substitute makes an additional cycle

2.5.16.

Benzimidazoles

Any compound derived from benzimidazole:

a) by replacing a hydrogen atom at the nitrogen atom with a not-replaced or replaced alkyl group or a not-replaced or replaced aroyl group;

b) in addition by replacing a hydrogen atom at the nitrogen atom of the imidazole cycle with a not-replaced or replaced (hetero)aryl group or a not-replaced or replaced aroyl group;

c) in addition by not replacing or replacing hydrogen atoms on the benzene ring of benzimidazole

2.5.17.

Diphenylethanamines

1,2-diphenylethan-1-amine, its enantiomers and any compound derived from them:

a) by not replacing or by replacing hydrogen atoms on one or both benzene rings with one or several identical or different substitutes;

b) in addition by not replacing or by replacing in the compounds referred to in Sub-paragraph "a" one or both hydrogen atoms of the amino group with a not-replaced or replaced alkyl group or by including it in the cycle;

c) in addition by replacing in the compounds referred to in Sub-paragraph "b" one carbon atom on one or both benzene rings with a nitrogen atom

2.5.18.

Derivatives of carbazole-3-carbonyl

Derivatives of carbazole-3-carbonyl that have been replaced at the carbazole ring in oxygen atom condition 1 with a not-replaced or replaced alkyl group

and condition 3 at carbonyl group is replaced with:

a) a not-replaced or replaced alkyl group, cycloalkyl group;

b) a not-replaced or replaced aromatic or heteroaromatic cycle;

c) a not-replaced or replaced alcoxy group, aryloxy group, heteryloxy group;

d) a replaced amino group

and any of the abovementioned compounds that has been additionally replaced in the carbazole ring

2.5.19.

Derivatives of pyrazole-3-carbonyl

Derivatives of pyrazole-3-carbonyl which in condition 3 at carbonyl group are replaced with:

• a not-replaced or replaced alkyl group or a cycloalkyl group;

• a not-replaced or replaced aromatic or heteroaromatic cycle;

• a not-replaced or replaced alcoxy group, aryloxy group, heteryloxy group;

• a replaced amino group

and in pyrazole cycle conditions 1 and 4 (one or both) not replaced or replaced with not-replaced or replaced alkyl groups or aryl groups and in condition 5 replaced with a not-replaced or replaced aryl group

2.5.20.

Derivatives of pyrazole-5-carbonyl

Derivatives of pyrazole-5-carbonyl which in condition 5 at carbonyl group are replaced with:

• a not-replaced or replaced alkyl group or a cycloalkyl group;

• a not-replaced or replaced aromatic or heteroaromatic cycle;

• a not-replaced or replaced alcoxy group, aryloxy group, heteryloxy group;

• a replaced amino group

and in pyrazole cycle conditions 1 and 4 (one or both) not replaced or replaced with not-replaced or replaced alkyl groups or aryl groups and in condition 3 replaced with a not-replaced or replaced aryl group

2.5.21.

2-phenylmorpholines

2-phenylmorpholine, its enantiomers and any compound derived from them:

a) by changing the benzene ring with a thiophene or pyridine ring;

b) by changing the morpholine cycle with a thiomorpholine cycle;

c) by replacing one or several hydrogen atoms on the benzene, thiophene or pyridine ring with a not-replaced or replaced alkyl group, alcoxy group, amide group, amino group, sulphonyl group or substitutes which form a cyclic structure supplementing the benzene, thiophene or pyridine ring;

d) by replacing one or several hydrogen atoms on the benzene, thiophene or pyridine ring with a hydroxyl group or halogen atom;

e) by replacing one or several hydrogen atoms on a morpholine or thiomorpholine cycle with a hydroxyl group, nitroso group, carbonyl group or not-replaced or replaced alkyl group

2.5.22.

Lysergamides (or amides of lysergic acid)

4,6,6a,7,8,9-hexahydroindol[4,3-fg]quinoline-9-carboxamide*****, its enantiomers and any compound derived from them:

a) by not replacing or by replacing one or two hydrogen atoms at the nitrogen atom in an amide group with not-replaced or replaced alkyl group(s) or substitutes that include a nitrogen atom in the atom cycle;

b) by not replacing or by replacing the hydrogen atom at the nitrogen atom in a hydrogenated quinoline cycle with a not-replaced or replaced alkyl group;

c) by not replacing or by replacing the hydrogen atom at the nitrogen atom in the indole cycle with a not-replaced or replaced alkyl group

2.5.23.

Derivatives of indoline-2-one-3-hydrazine carbonyl

Derivatives of indole-2-one-3-hydrazine carbonyl which are replaced at the nitrogen atom in indoline-2-one cycle with a not-replaced or replaced alkyl group and in condition 3 replaced at carbonyl group with:

• a not-replaced or replaced alkyl group or a cycloalkyl group;

• a not-replaced or replaced aromatic or heteroaromatic cycle;

• a not-replaced or replaced alcoxy group, aryloxy group, heteryloxy group;

• a replaced amino group;

and any of the abovementioned compounds in which hydrazine group hydrogen atom is replaced with an alkyl group, or replaced in indoline-2-one cycle

2.5.24.

Gamma-carbonyl-1-ones

Any compound derived from 2,5-dihydro-1H-pyrido[4,3-b]indolo-1-one:

a) by replacing hydrogen atom in condition 5 with a not-replaced or replaced alkyl group or a cycloalkyl group;

b) by replacing hydrogen atom in condition 2 with a not-replaced or replaced alkyl group, cycloalkyl group, a not-replaced or replaced aromatic or heteroaromatic cycle, and any of the abovementioned compounds that has been additionally replaced in the carboline cycle

2.5.25.

Acetylfentanyls

N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide and any compound derived from N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide, if one or several conditions have been met:

a) by replacing one or several hydrogen atoms on one or both benzene rings with one or several identical or different halogen atoms or alcoxy groups;

b) by replacing one or several hydrogen atoms in piperidine cycle condition 2, 3, 5, or 6 with a not-replaced or replaced alkyl group;

c) by replacing one or several ethylene group hydrogen atoms with a not-replaced or replaced alkyl group or hydroxyl group;

d) by replacing one or several hydrogen atoms in acetyl group with a not-replaced or replaced alkyl group(s), alkenyl group, methoxy group or by including a carbon atom in a cycle which may be replaced, including by creating supplementing cycles;

e) by replacing ethylene group with a methylene group;

f) by replacing hydrogen atom in condition 5 of piperidine cycle with a replaced or not-replaced phenyl group or ester group;

g) by changing the benzene ring present in N-(1-phenethylpiperidin-4-yl) group with another cyclic structure, different from the benzene ring, which may be replaced;

h) by changing the benzene ring of N-phenyl group with another saturated structure, different from the benzene ring, which may be replaced

Notes.

1. * If the substance is also referred to in Annex 2 or 3 to this Regulation, it shall not be applicable to Annex 1.

2. ** Except ketamine.

3. *** Except cannabidiol.

4. **** Except serotonin, sumatriptan, zolmitriptan.

5. ***** Except ergometrine, ergotamine, methylergometrine, methysergide.

 

Annex 2
Cabinet Regulation No. 847
8 November 2005

[10 October 2017]

Narcotic Substances, Psychotropic Substances and Precursors to be Controlled in Latvia

Schedule II

(Very dangerous narcotic substances and equivalent psychotropic substances permitted for medical and scientific use)

1. Substances classified in conformity with Schedule I of the Single Convention on Narcotic Drugs of 30 March 1961:

No.

International non-proprietary name (INN)/trivial name

CAS No.

1.1. acetylmethadol 509-74-0
1.2. alfentanil 71195-58-9
1.3. allylprodine 25384-17-2
1.4. alphameprodine 468-51-9
1.5. alphamethadol 17199-54-1
1.6. alphaprodine 77-20-3
1.7. anileridine 144-14-9
1.8. benzethidine 3691-78-9
1.9. benzylmorphine 14297-87-1
1.10. betacetylmethadol 17199-59-6
1.11. betameprodine 468-50-8
1.12. betamethadol 17199-55-2
1.13. betaprodine 468-59-7
1.14. bezitramide 15301-48-1
1.15. dextromoramide 357-56-2
1.16. diampromide 552-25-0
1.17. diethylthiambutene 86-14-6
1.18. difenoxin 28782-42-5
1.19. dihydroetorphine 14357-76-7
1.20. dihydromorphine 509-60-4
1.21. dimenoxadol 509-78-4
1.22. dimepheptanol 545-90-4
1.23. dimethylthiambutene 524-84-5
1.24. dioxaphetyl butyrate 467-86-7
1.25. diphenoxylate 915-30-0
1.26. dipipanone 467-83-4
1.27. drotebanol 3176-03-2
1.28. ecgonine, esters thereof and derivatives which may be converted into ecognine and cocaine 481-37-8
1.29. ethylmethylthiambutene 441-61-2
1.30. etoxeridine 469-82-9
1.31. etonitazene 911-65-9
1.32. phenadoxone 467-84-5
1.33. phenampromide 129-83-9
1.34. phenazocine 127-35-5
1.35. phenomorphan 468-07-5
1.36. phenoperidine 562-26-5
1.37. fentanyl 437-38-7
1.38. furethidine 2385-81-1
1.39. hydrocodone 125-29-1
1.40. hydromorphinol 2183-56-4
1.41. hydromorphone 466-99-9
1.42. hydroxypethidine 468-56-4
1.43. isomethadone 466-40-0
1.44. ketobemidone 469-79-4
1.45. clonitazene 3861-76-5
1.46. codoxime 7125-76-0
1.47. cocaine 50-36-2
1.48. levophenacylmorphan 10061-32-2
1.49. levomethorphan 125-70-2
1.50. levomoramide 5666-11-5
1.51. levorphanol 77-07-6
1.52. methadone 76-99-3
1.53. methadone intermediate 125-79-1
1.54. metazocine 3734-52-9
1.55. methyldesorphine 16008-36-9
1.56. methyldihydromorphine 509-56-8
1.57. metopon 143-52-2
1.58. moramide intermediate 3626-55-9
1.59. morpheridine 469-81-8
1.60. morphine 57-27-2
1.61. morphine methobromide and other morphine derivatives containing pentavalent nitrogen 125-23-5
1.62. morphine-N-oxide 639-46-3
1.63. myrophine 467-18-5
1.64. nicomorphine 639-48-5
1.65. noracymethadol 1477-39-0
1.66. norlevorphanol 1531-12-0
1.67. normethadone 467-85-6
1.68. normorphine 466-97-7
1.69. norpipanone 561-48-8
1.70. oxycodone 76-42-6
1.71. oxymorphone 76-41-5
1.72. opium not specified
1.73. pethidine 57-42-1
1.74. pethidine intermediate A 3627-62-1
1.75. pethidine intermediate B 77-17-8
1.76. pethidine intermediate C 3627-48-3
1.77. piminodine 13495-09-5
1.78. piritramide 302-41-0
1.79. proheptazine 77-14-5
1.80. properidine 561-76-2
1.81. racemethorphan 510-53-2
1.82. racemoramide 545-59-5
1.83. racemorphan 297-90-5
1.84. remifentanil 132875-61-7
1.85. sufentanil 56030-54-7
1.86. thebacon 466-90-0
1.87. thebaine 115-37-7
1.88. tilidine 20380-58-9
1.89. trimeperidine 64-39-1

2. Substances classified in conformity with Schedule II of the Single Convention on Narcotic Drugs of 30 March 1961:

No.

International non-proprietary name (INN)/trivial name

CAS No.

2.1. acetyldihydrocodeine 3861-72-1
2.2. dextropropoxyphene 469-62-5
2.3. dihydrocodeine 125-28-0
2.4. ethylmorphine 76-58-4
2.5. pholcodine 509-67-1
2.6. codeine 76-57-3
2.7. nicocodine 3688-66-2
2.8. nicodicodine 808-24-2
2.9. norcodeine 467-15-2
2.10. propiram 15686-91-6

3. Substances classified in conformity with Schedule II of the Convention on Psychotropic Substances of 21 February 1971:

No.

International non-proprietary name (INN)/trivial name

CAS No.

3.1. zipeprol 34758-83-3
3.2. dronabinol (delta-9-tetrahydrocannabinol and its stereochemical variants) 1972- 08-3 (CAS No. indicated for substance "dronabinol")
3.3. phencyclidine (PCP) 77-10-1
3.4. phenmetrazine 134-49-6
3.5. mecloqualone 340-57-8
3.6. methaqualone 72-44-6
3.7. methylphenidate 113-45-1
3.8. secobarbital 76-73-3
3.9. gamma-hydroxybutyric acid (GHB) 591-81-1
3.10. methylmorphenate 231299-92-6

4. Substances classified in conformity with Schedule III of the Convention on Psychotropic Substances of 21 February 1971:

No.

International non-proprietary name (INN)/trivial name

CAS No.

4.1. amobarbital 57-43-2
4.2. buprenorphine 52485-79-7
4.3. butalbital 77-26-9
4.4. cyclobarbital 52-31-3
4.5. flunitrazepam 1622-62-4
4.6. glutethimide 77-21-4
4.7. hexobarbital 56-29-1
4.8. pentazocine 359-83-1
4.9. pentobarbital 76-74-4

5. Narcotic substance, illicit circulation and abuse of which may endanger health

No.

International non-proprietary name (INN)/trivial name

CAS No.

5.1. tapentadol 175591-09-0

 

Annex 3
Cabinet Regulation No. 847
8 November 2005

[10 October 2017]

Narcotic Substances, Psychotropic Substances and Precursors to be Controlled in Latvia

Schedule III

(Dangerous psychotropic substances that can be abused)

Substances classified in conformity with Schedule IV of the Convention on Psychotropic Substances of 21 February 1971:

No.

International non-proprietary name (INN)/trivial name

CAS No.

1. Allobarbital 52-43-7
2. Alprazolam 28981-97-7
3. Amfepramone 90-84-6
4. Aminorex 2207-50-3
5. Barbital 57-44-3
6. Benzfetamine 156-08-1
7. Bromazepam 1812-30-2
8. Brotizolam 57801-81-7
9. Butobarbital 77-28-1
10. Cephedrine 67055-59-8
11. Delorazepam 2894-67-9
12. Diazepam 439-14-5
13. Ephedrine* 299-42-3
14. Estazolam 29975-16-4
15. Ethchlorvynol 113-18-8
16. Ethinamate 126-52-3
17. Ethyl loflazepate 29177-84-2
18. Phenatine 139-68-4
19. Fenazepam 51753-57-2
20. Fencamfamin 1209-98-9
21. Phendimetrazine 634-03-7
22. Phenobarbital 50-06-6
23. Fludiazepam 3900-31-0
24. Flurazepam 17617-23-1
25. Halazepam 23092-17-3
26. Haloxazolam 59128-97-1
27. Chlordiazepoxide 58-25-3
28. Camazepam 36104-80-0
29. Ketazolam 27223-35-4
30. Clobazam 22316-47-8
31. Cloxazolam 24166-13-0
32. Clonazepam 1622-61-3
33. Clorazepate 23887-31-2
34. Clotiazepam 33671-46-4
35. Lefetamine (SPA) 7262-75-1
36. Loprazolam 61197-73-7
37. Lorazepam 846-49-1
38. Lormetazepam 848-75-9
39. Mazindol 22232-71-9
40. Medazepam 2898-12-6
41. Meprobamate 57-53-4
42. Methylphenobarbital 115-38-8
43. Methyprylon 125-64-4
44. Mesocarb 34262-84-5
45. Midazolam 59467-70-8
46. Nimetazepam 2011-67-8
47. Nitrazepam 146-22-5
48. Nordazepam 1088-11-5
49. Oxazepam 604-75-1
50. Oxazolam 24143-17-7
51. Pemoline 2152-34-3
52. Pinazepam 52463-83-9
53. Pipradrol 467-60-7
54. Pyrovalerone 3563-49-3
55. Prazepam 2955-38-6
56. Propanidid 1421-14-3
57. Pseudoephedrine* 90-82-4
58. Secbutabarbital 125-40-6
59. Temazepam 846-50-4
60. Tetrazepam 10379-14-3
61. Tofisopam 22345-47-7
62. Triazolam 28911-01-5
63. Trihexyphenidyl 144-11-6
64. Vinylbital 2430-49-1
65. Zolpidem 82626-48-0
66. Zopiclone 43200-80-2
67. Tramadol 27203-92-5
68. Derivative of alprazolam triazolo-benzophenone Not available
69. Deschloroetizolam 40054-73-7
70. Metizolam 40054-68-0
71. Nitrazolam 28910-99-8
72. Pyrazolam 39243-02-2

Note. * The procedures specified by regulatory enactments in the field of pharmacy shall also be observed during control.

 


Translation © 2018 Valsts valodas centrs (State Language Centre)

 
Document information
Status:
In force
in force
Issuer: Cabinet of Ministers Type: regulation Document number: 847Adoption: 08.11.2005.Entry into force: 11.11.2005.Publication: Latvijas Vēstnesis, 180, 10.11.2005.
Language:
Related documents
  • Amendments
  • Changes legal status of
  • Issued pursuant to
  • Explanations
121086
{"selected":{"value":"16.10.2019","content":"<font class='s-1'>16.10.2019.-...<\/font> <font class='s-3'>Sp\u0113k\u0101 eso\u0161\u0101<\/font>"},"data":[{"value":"16.10.2019","iso_value":"2019\/10\/16","content":"<font class='s-1'>16.10.2019.-...<\/font> <font class='s-3'>Sp\u0113k\u0101 eso\u0161\u0101<\/font>"},{"value":"10.01.2019","iso_value":"2019\/01\/10","content":"<font class='s-1'>10.01.2019.-15.10.2019.<\/font> <font class='s-2'>V\u0113sturisk\u0101<\/font>"},{"value":"16.10.2017","iso_value":"2017\/10\/16","content":"<font class='s-1'>16.10.2017.-09.01.2019.<\/font> <font class='s-2'>V\u0113sturisk\u0101<\/font>"},{"value":"17.03.2017","iso_value":"2017\/03\/17","content":"<font class='s-1'>17.03.2017.-15.10.2017.<\/font> <font class='s-2'>V\u0113sturisk\u0101<\/font>"},{"value":"01.05.2016","iso_value":"2016\/05\/01","content":"<font class='s-1'>01.05.2016.-16.03.2017.<\/font> <font class='s-2'>V\u0113sturisk\u0101<\/font>"},{"value":"01.06.2015","iso_value":"2015\/06\/01","content":"<font class='s-1'>01.06.2015.-30.04.2016.<\/font> <font class='s-2'>V\u0113sturisk\u0101<\/font>"},{"value":"23.08.2014","iso_value":"2014\/08\/23","content":"<font class='s-1'>23.08.2014.-31.05.2015.<\/font> <font class='s-2'>V\u0113sturisk\u0101<\/font>"},{"value":"24.05.2013","iso_value":"2013\/05\/24","content":"<font class='s-1'>24.05.2013.-22.08.2014.<\/font> <font class='s-2'>V\u0113sturisk\u0101<\/font>"},{"value":"23.02.2013","iso_value":"2013\/02\/23","content":"<font class='s-1'>23.02.2013.-23.05.2013.<\/font> <font class='s-2'>V\u0113sturisk\u0101<\/font>"},{"value":"16.08.2012","iso_value":"2012\/08\/16","content":"<font class='s-1'>16.08.2012.-22.02.2013.<\/font> <font class='s-2'>V\u0113sturisk\u0101<\/font>"},{"value":"01.01.2012","iso_value":"2012\/01\/01","content":"<font class='s-1'>01.01.2012.-15.08.2012.<\/font> <font class='s-2'>V\u0113sturisk\u0101<\/font>"},{"value":"01.06.2011","iso_value":"2011\/06\/01","content":"<font class='s-1'>01.06.2011.-31.12.2011.<\/font> <font class='s-2'>V\u0113sturisk\u0101<\/font>"},{"value":"21.05.2011","iso_value":"2011\/05\/21","content":"<font class='s-1'>21.05.2011.-31.05.2011.<\/font> <font class='s-2'>V\u0113sturisk\u0101<\/font>"},{"value":"28.11.2009","iso_value":"2009\/11\/28","content":"<font class='s-1'>28.11.2009.-20.05.2011.<\/font> <font class='s-2'>V\u0113sturisk\u0101<\/font>"},{"value":"16.05.2009","iso_value":"2009\/05\/16","content":"<font class='s-1'>16.05.2009.-27.11.2009.<\/font> <font class='s-2'>V\u0113sturisk\u0101<\/font>"},{"value":"11.11.2005","iso_value":"2005\/11\/11","content":"<font class='s-1'>11.11.2005.-15.05.2009.<\/font> <font class='s-2'>Pamata<\/font>"}]}
16.10.2019
87
0
  • Twitter
  • Facebook
  • Draugiem.lv
 
0
Latvijas Vestnesis, the official publisher
ensures legislative acts systematization
function on this site.
All Likumi.lv content is intended for information purposes.
About Likumi.lv
News archive
Useful links
Contacts
For feedback
Terms of service
Privacy policy
Cookies
RSS logo
Latvijas Vēstnesis "Everyone has the right to know about his or her rights."
Article 90 of the Constitution of the Republic of Latvia
© Official publisher "Latvijas Vēstnesis"
ISO 9001:2008 (quality management system)
ISO 27001:2013 (information security) Kvalitātes balva